Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: Has victory been achieved?

American Journal of Transplantation

Volumn 7, Issue 9, 2007, Pages 2062-2063

  Avery, R K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; EDITORIAL; HUMAN; PRIORITY JOURNAL; VIREMIA;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VIREMIA;

EID: 34547838837     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01925.x     Document Type: Editorial

References (10)

1. Asberg A, Humar A, Rollag H et al. Oral valganciclovir is non-inferior to IV ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007.
2. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther 2004 2:27 41.
3. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4:611 620.
4. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004 4:1635 1642.
5. Humar A, Siegal D, Moussa G, Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005 192:1154 1157.
6. Diaz-Pedroche C, Lumbreras C, San Juan R et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006 82:30 35.
7. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006 6:2134 2143.
8. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005 79:85 90.
9. Mattes FM, Hainsworth EG, Hassan-Walker AF et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005 191:89 92.
10. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002 185:20 27.